August 7, 2010 -- China Kanghui Holdings reported increased Q2 results and detailed plans for its $69 million IPO on the NYSE; Sangon Biotech, a Shanghai life science research service company, received $10 million in VC from Qiming Ventures; the Scientific American devoted a special section to China’s biopharma innovation; the SFDA will soon complete a national network to monitor all 307 drugs on the Essential Drug List; and recently spurned merger partner WuXi PharmaTech increased its guidance for 2010 while suitor Charles River trimmed its 2010 outlook. More details….
